Sign in

NCT07187921Completed

Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers

Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers (eDROP-AD)

Source: ClinicalTrials.gov · Last updated 9 Dec 2025

Brief summary (registry, in English)

This is an observational study that will collect blood from a finger prick (Capitainer SEP10 single channel device) and assess the accuracy of pTau-217 testing in comparison to previously collected venous blood samples from the same individuals.

Status (registry)
Completed
Study type
Observational
Enrollment
49 (actual)
First submitted
11 Sept 2025
Start date
29 Sept 2025
Primary completion date
12 Nov 2025
Lead sponsor
Banner Health
NCT number
NCT07187921

What you commit to

  • Study type: Observational
  • Participants enrolled: 49
  • From 29 Sept 2025 to the primary completion date, 12 Nov 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • \-

Who the study is looking for

  • Able and willing to provide informed consent for the eDROP-AD study.
  • Enrolled in the Draw-10 study at Banner Alzheimer's Institute-Phoenix and provided at least one venous blood sample.
  • Able and willing to fully comply with study procedures defined in this protocol.
  • Written and spoken fluency in the English language.

Age in the registry: 50 years to 80 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Banner Alzheimer's Institute
Coordinator of this site? Confirm its status
PhoenixUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.